Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment. METHODS: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states. RESULTS: Preferences decreased with reduced treatment responsiveness and with increasing toxicity. CONCLUSIONS: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations.

Original publication

DOI

10.1038/sj.bjc.6605187

Type

Journal article

Journal

Br J Cancer

Publication Date

04/08/2009

Volume

101

Pages

387 - 389

Keywords

Adult, Aged, Antineoplastic Agents, Australia, Cross-Sectional Studies, Female, Health Status, Humans, Male, Melanoma, Middle Aged, United Kingdom